Milrinone inhalation

ApprovedSmall molecule

Milrinone inhalation is one of 34 small molecule programs targeting Pulmonary Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary HypertensionActive, not recruiting

Pulmonary HypertensionApproved

Active, not recruiting

Competition

Competitive Landscape

154 competitors in Pulmonary Hypertension

#DrugCompanyPhaseTrials

Reata

Biogen

Phase 3

2 2

Diamox

Teva

Phase 3

2 3

Crestor

AstraZeneca

Phase 3

1 4

Lexapro

AbbVie

Phase 3

1 5

Accrufer

SShield Therapeutics

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Distilled Water

GSK

Phase 3

2 8

Diluent

Sanofi

Phase 3

1 9

Remodulin

United Therapeutics

Phase 3

1 10

Iloprost Inhalation

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Hypertension1 trial

Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension

Recruiting·ZZagazig University·Phase 4·NCT04484675·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Milrinone inhalation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Milrinone inhalation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Milrinone inhalation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zagazig University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: ZZagazig University

Milrinone inhalation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Hypertension1 trial

References

Drug Info

Quick Facts

Related News